Medicamen Organics Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 1,460,000 (47%) | — | ₹496 Cr |
| NII (HNI) | — | 440,000 (14%) | — | ₹150 Cr |
| Retail | — | 1,028,000 (33%) | — | ₹350 Cr |
| Market Maker | — | 172,000 (6%) | — | ₹6 Cr |
| Σ Total | — | 3,100,000 (100%) | — | ₹10,540 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 4,000 | ₹136,000 |
| Retail (Max) | 13 | 52,000 | ₹1,768,000 |
| S-HNI (Min) | 14 | 56,000 | ₹1,904,000 |
| B-HNI (Min) | 67 | 268,000 | ₹9,112,000 |
Financial Statements Amount in ₹ Lakhs
| Metric | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Revenue | 2,529 | 2,296 | 2,119 |
| Profit After Tax | 240 | 96 | 9 |
| Net Worth | 1,518 | 852 | 756 |
| Total Assets | 3,858 | 3,212 | 2,707 |
| Reserves & Surplus | 658 | 252 | 156 |
| Total Borrowing | 1,266 | 1,180 | 1,025 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Funding of expenses proposed to be incurred towards Product registration in the international markets; –
- Plant updation and increase in production capacity; –
- Funding working capital requirements of our Company; and –
- General Corporate Purposes. –
Company Overview
Medicamen Organics Limited was incorporated in 1995 and develops, manufactures, and distributes pharmaceutical dosages including generic dosages in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions and dry powders for the Government (including State Governments and Central Governments) and private entities as a contract manufacturer/third party manufacturer.
The company's product list comprises 84 products and offers a wide range of drugs such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral and non-steroidal anti-inflammatory drugs (NSAIDS).
The company's products are marketed throughout India as well as in African, CIS, and South East Asian countries such as Congo, Benin, Kameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya through third-party distributors.
The company has two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, covering an area of 21,536 Sq. Ft. As on September 30, 2023, the company has entered into contract manufacturing with 38 domestic partners and 12 merchant exporters.
As of September 30, 2023, the company employed a total of 116 people.